{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Koshiol J"],"funding":["Academia Sinica"],"pagination":["833-842"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12332984"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["54(6)"],"pubmed_abstract":["<h4>Background</h4>Clinical and experimental studies suggest immunologic proteins contribute to hepatocellular carcinoma (HCC) development.<h4>Aim</h4>To evaluate circulating immunologic markers and HCC risk.<h4>Methods</h4>From a Taiwanese cohort of chronically hepatitis B virus (HBV)-infected individuals followed over time (REVEAL-HBV), we sampled 175 who developed HCC, 117 cirrhosis only, and 165 non-cirrhotic controls. From a similar Taiwanese cohort of chronically hepatitis C virus (HCV)-infected individuals (REVEAL-HCV), we included 94 individuals who developed HCC, 68 cirrhosis only and 100 non-cirrhotic controls. We compared pre-diagnostic plasma levels of 102 markers in HCC cases to non-cirrhotic and cirrhotic controls using polytomous logistic regression. A priori markers include"],"journal":["Alimentary pharmacology & therapeutics"],"pubmed_title":["Immunologic markers and risk of hepatocellular carcinoma in hepatitis B virus- and hepatitis C virus-infected individuals."],"pmcid":["PMC12332984"],"funding_grant_id":["101‐2314‐B‐001‐005‐MY3"],"pubmed_authors":["Lee MH","Chen CJ","McGlynn KA","O'Brien TR","Yu K","Yang HI","Liu Z","Petrick JL","Pfeiffer RM","Koshiol J","Argirion I","Kim Lam T","Pinto L","Hildesheim A"],"additional_accession":[]},"is_claimable":false,"name":"Immunologic markers and risk of hepatocellular carcinoma in hepatitis B virus- and hepatitis C virus-infected individuals.","description":"<h4>Background</h4>Clinical and experimental studies suggest immunologic proteins contribute to hepatocellular carcinoma (HCC) development.<h4>Aim</h4>To evaluate circulating immunologic markers and HCC risk.<h4>Methods</h4>From a Taiwanese cohort of chronically hepatitis B virus (HBV)-infected individuals followed over time (REVEAL-HBV), we sampled 175 who developed HCC, 117 cirrhosis only, and 165 non-cirrhotic controls. From a similar Taiwanese cohort of chronically hepatitis C virus (HCV)-infected individuals (REVEAL-HCV), we included 94 individuals who developed HCC, 68 cirrhosis only and 100 non-cirrhotic controls. We compared pre-diagnostic plasma levels of 102 markers in HCC cases to non-cirrhotic and cirrhotic controls using polytomous logistic regression. A priori markers include","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2026-04-15T19:22:08.9Z","creation":"2026-04-07T14:01:03.019Z"},"accession":"S-EPMC12332984","cross_references":{"pubmed":["34286851"],"doi":["10.1111/apt.16524"]}}